SARASOTA, Fla., Aug. 4, 2023
/PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq:INVO) ("INVO" or
the "Company"), a healthcare services fertility company focused on
expanding access to advanced treatment worldwide with its INVOcell®
medical device and the intravaginal culture ("IVC") procedure it
enables, today announced the pricing of its public offering of
1,580,000 units, with each unit consisting of one share of common
stock and two warrants, each to purchase one share of common stock.
Each unit is being sold at a public offering price
of $2.85. The warrants will be immediately exercisable at a
price of $2.85 per share and will
expire five years from the date of issuance. The shares of common
stock and accompanying warrants can only be purchased together in
this offering, but will be issued separately and will be
immediately separable upon issuance.
Gross proceeds, before deducting placement agent fees and other
offering expenses, are expected to be approximately $4.5
million. The offering is expected to close on August 8, 2023,
subject to customary closing conditions.
Maxim Group LLC is acting as sole placement agent in
connection with this offering.
The securities described above are being offered pursuant to a
registration statement on Form S-1, as amended (File No.
333-273174) (the "Registration Statement"), which was declared
effective by the Securities and Exchange Commission (the
"SEC") on August 3, 2023. The offering is being made only by
means of a prospectus which is a part of the Registration
Statement. A preliminary prospectus relating to the offering has
been filed with the SEC. Copies of the final prospectus
relating to this offering, when available, will be filed with
the SEC and may be obtained from Maxim Group
LLC, 300 Park Avenue, 16th Floor, New York,
NY 10022, at (212) 895-3745.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About INVO Bioscience
We are a healthcare services fertility company dedicated to
expanding the assisted reproductive technology ("ART") marketplace
by making fertility care accessible and inclusive to people around
the world. Our commercialization strategy is focused on the opening
of dedicated "INVO Centers" offering the INVOcell® and IVC
procedure (with three centers in North
America now operational), the acquisition of US-based,
profitable in vitro fertilization ("IVF") clinics and the sale and
distribution of our technology solution into existing fertility
clinics. Our proprietary technology, INVOcell®, is a revolutionary
medical device that allows fertilization and early embryo
development to take place in vivo within the woman's body. This
treatment solution is the world's first intravaginal culture
technique for the incubation of oocytes and sperm during
fertilization and early embryo development. This technique,
designated as "IVC", provides patients a more natural, intimate,
and more affordable experience in comparison to other ART
treatments. We believe the IVC procedure can deliver comparable
results at a fraction of the cost of traditional IVF and is a
significantly more effective treatment than intrauterine
insemination ("IUI"). For more information, please visit
www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties, and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE: INVO Bioscience, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-announces-pricing-of-4-5-million-public-offering-301893605.html
SOURCE INVO Bioscience, Inc.